论文部分内容阅读
目的 观察糖尿病克敏胶囊降低血糖的药理作用。方法 用 ONE TOUCH BASIC微量血糖测试仪检测用药前后的血糖和葡萄糖耐量试验中的血糖,放免法测定C肽。结果 糖尿病克敏胶囊 1.5 g/kg剂量组对糖尿病小鼠具有明显的降低血糖作用。糖尿病小鼠糖耐量试验表明1.5g/kg剂量组淀粉应用前、用药 1.5 h及 3 h血糖分别是(13.6±2.9)、(19.3±4.和(14.2±3.7) mmol/L,对照组相应时相血糖分别是(12.8±2.8/L、(23.2±3.1)和(19.6±3.2)mmol/L,表明该药增加糖耐量。用药前后胰岛素用量分别是(31.6±17.5)U/d和(21.2±11.7)U/d,差异有显著性(P<0.05)。C肽用药前后测定结果分别是(0.O96±0.091)pmol/L和(0.152±0.107)pmol/L,差异有显著性(P<.05)。结论 糖尿病克敏胶囊具有降低STZ糖尿病小鼠的血糖,增加其糖耐量,减少胰岛素用量及升高血清C肽水平作用。
Objective To observe the pharmacological effects of Diabetes Kemin capsules in lowering blood glucose. Methods One-to-one TOUCH BASIC micro-glucose meter was used to measure blood glucose in blood glucose and glucose tolerance test before and after drug administration, and C-peptide was measured by radioimmunoassay. Results Diabetic Kemin capsule 1.5 g/kg dose group had obvious hypoglycemic effect on diabetic mice. Glucose tolerance test in diabetic mice showed that 1.5 g/kg glucose in the 1.5 g/kg group was (13.6±2.9), (19.3±4. and (14.2±3.7) mmol/L), and the control group had The phase glucose was (12.8±2.8/L, (23.2±3.1), and (19.6±3.2) mmol/L, respectively), indicating that the drug increased glucose tolerance. The insulin dosage before and after treatment was (31.6±17.5) U/d and ( 21.2±11.7)U/d, the difference was significant (P<0.05).The results before and after administration of C peptide were (0.O96±0.091) pmol/L and (0.152±0.107) pmol/L, respectively. The difference was significant. (P<.05). Conclusion Diabetes Kemin Capsule can reduce blood glucose, increase glucose tolerance, decrease insulin dosage and increase serum C peptide level in STZ diabetic mice.